Massive Bio Unveils Patient Connect: A Global Solution for Personalizing Access to Cancer Clinical Trials
Massive Bio Launches Patient Connect: A Revolutionary Platform for Global Cancer Clinical Trial Access Massive Bio, a global frontrunner in AI-driven cancer clinical trial enrollment, has unveiled Patient Connect, a…
Cellworks Predicts PARPi Benefits in Ovarian, Pancreatic, Prostate, and Triple-Negative Breast Cancers
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, has announced new findings from a study using its Cellworks Platform to predict homologous recombination deficiency…
PharmaLegacy Acquires BTS Research, Expands Preclinical Services into North America
PharmaLegacy Laboratories, a leading provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). This acquisition marks…
ImmunoPrecise Antibodies (IPA) Announces Q1 Fiscal 2025 Financial Results and Key Business Highlights
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutics research and technology company, has announced its financial results for the first quarter of fiscal 2025, ending on July 31, 2024. All…
Novatek Names Dr. Yooni Kim as Executive President for Asia Pacific to Drive Global Growth
Novotech, a global contract research organization (CRO), has announced the appointment of Dr. Yooni Kim as Executive President of Asia Pacific (APAC), effective September 1, 2024. This move reflects Novotech’s…
Tempus Announces Four Abstracts Accepted for ESMO 2024 Congress
Tempus AI, Inc. (NASDAQ: TEM), a leader in advancing precision medicine through AI technology, has announced that four of its abstracts have been accepted for presentation at the European Society…
FDA Approves Ocrevus Zunovo™ First Twice-a-Year 10-Minute MS Injection
Genentech, part of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for treating both relapsing multiple sclerosis (RMS)…
Dupixent Approved in U.S. as First Treatment for Adolescent CRSwN
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has granted approval for Dupixent® (dupilumab) as an add-on maintenance therapy for adolescents…
Japan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19…
Enhertu Shows Strong Efficacy in HER2-Positive Breast Cancer with Brain Metastases
Results from the DESTINY-Breast12 Phase IIIb/IV trial reveal that Enhertu (trastuzumab deruxtecan) demonstrated significant overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, including those with brain…
FDA Approves Roche’s Tecentriq Hybreza First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), the first subcutaneous (SC) PD-(L)1 inhibitor for cancer…
FDA Approves EBGLYSS™ for Moderate-to-Severe Atopic Dermatitis in Ages 12+
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved EBGLYSS™ (lebrikizumab-lbkz), an IL-13 inhibitor, for treating moderate-to-severe atopic dermatitis (eczema) in adults…